Victor Jia Wei Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Victor Jia Wei Zhang has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Julian David Gillmore
University College London, Royal Free Hospital
2 shared publications - Mary M. Reilly
Department of Neuromuscular Diseases UCL Queen Square Institute of Neurology London UK
2 shared publications - Alexander Martin Rossor
Centre for Neuromuscular Diseases, Department of Neuromuscular Diseases UCL Queen Square Institute of Neurology London UK
1 shared publication - Ata Siddiqui
Guy's and St Thomas’ NHS Foundation Trust
1 shared publication - Chandrashekar Hoskote
Lysholm Department of Neuroradiology National Hospital for Neurology and Neurosurgery (NHNN) London UK
1 shared publication - David Noel Vaughan
Florey Department of Neuroscience and Mental Health, The University of Melbourne, Melbourne, Melbourne, Australia
1 shared publication
Latest Publications
- 11 December 2025
- Published by Wiley in Journal of the Peripheral Nervous System
- Vol. 30 (4) , e70088
Impact of High‐Dose Tafamidis on Hereditary ATTR ( ATTRv ) Amyloidosis With Central Nervous System Involvement: Two Case Reports With Clinical, Radiological and Cerebrospinal Fluid Follow Up
Background: Treatment options for central nervous system (CNS) manifestations of ATTRv amyloidosis remain limited, with no disease‐modifying therapy. However, previous case series have indicated that tafamidis (a transthyretin stabiliser) crosses the blood–brain barrier in small quantities. We present long‐term follow‐up data on two patients with CNS manifestations of ATTRv who received high‐dose (61 mg) oral tafamidis. Methods: Patient one is a 48‐year‐old man with p.Gly73Ala ATTRv peripheral neuropathy and commenced on gene‐silencing therapy. He was subsequently diagnosed with early ATTRv CNS involvement, prompting the addition of tafamidis since age 45. Patient two is a 27‐year‐old woman with p.Gly67Arg ATTRv with significant CNS involvement resulting in epilepsy and encephalopathy. Since age 21, she has been on gene‐silencing therapy and tafamidis. Results: Following 3 years of therapy, patient one has remained clinically asymptomatic. However, brain magnetic resonance imaging (MRI) and cerebrospinal fluid assessment have demonstrated progression of his CNS ATTRv. Followed 6 years of therapy, patient two has continued to have seizures requiring escalation of anti‐seizure medications and MRI brain has shown progression of CNS disease. Conclusions: In our two patients, progression of CNS disease occurred whilst on high‐dose tafamidis, highlighting the importance of further studies into the monitoring and treatment of CNS manifestations of ATTRv.
- 11 December 2025
- Published by Wiley in Journal of the Peripheral Nervous System
- Vol. 30 (4) , e70088
Impact of High‐Dose Tafamidis on Hereditary ATTR ( ATTRv ) Amyloidosis With Central Nervous System Involvement: Two Case Reports With Clinical, Radiological and Cerebrospinal Fluid Follow Up
Background: Treatment options for central nervous system (CNS) manifestations of ATTRv amyloidosis remain limited, with no disease‐modifying therapy. However, previous case series have indicated that tafamidis (a transthyretin stabiliser) crosses the blood–brain barrier in small quantities. We present long‐term follow‐up data on two patients with CNS manifestations of ATTRv who received high‐dose (61 mg) oral tafamidis. Methods: Patient one is a 48‐year‐old man with p.Gly73Ala ATTRv peripheral neuropathy and commenced on gene‐silencing therapy. He was subsequently diagnosed with early ATTRv CNS involvement, prompting the addition of tafamidis since age 45. Patient two is a 27‐year‐old woman with p.Gly67Arg ATTRv with significant CNS involvement resulting in epilepsy and encephalopathy. Since age 21, she has been on gene‐silencing therapy and tafamidis. Results: Following 3 years of therapy, patient one has remained clinically asymptomatic. However, brain magnetic resonance imaging (MRI) and cerebrospinal fluid assessment have demonstrated progression of his CNS ATTRv. Followed 6 years of therapy, patient two has continued to have seizures requiring escalation of anti‐seizure medications and MRI brain has shown progression of CNS disease. Conclusions: In our two patients, progression of CNS disease occurred whilst on high‐dose tafamidis, highlighting the importance of further studies into the monitoring and treatment of CNS manifestations of ATTRv.
- Open Access
- 1 October 2025
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 11 (5) , e200304
Peripheral Neuropathy in p.Val142Ile (Val122Ile) Variant Hereditary Transthyretin-Mediated Amyloidosis
P.Val142Ile (p.V142I) is one of the most common pathogenic transthyretin (TTR) variants typically presents as transthyretin amyloid cardiomyopathy (ATTRv-CM), although frequent concurrent peripheral nerve involvement has been reported (94%). We aimed to characterize the polyneuropathy in p.V142I ATTR amyloidosis (ATTRv-PN) from the UK amyloidosis cohort. We performed a retrospective cohort study of all confirmed p.V142I Variant Transthyretin Amyloidosis (ATTRv) individuals in the National Hospital for Neurology and Neurosurgery Inherited Neuropathy Clinic between January 2019 and October 2024. Because presence of ATTRv-PN was required to access disease-modifying therapy for amyloidosis during this time, all individuals with p.V142I ATTRv were evaluated for neuropathy, providing an unselected cohort. We identified 52 individuals with p.V142I ATTRv among whom the clinical presentation was cardiac in 47 (90%) and neuropathic in 5 (10%). Age at diagnosis was 71.3 ± 12.2 years. Twenty of the 52 individuals (38%) had symptoms suggestive of neuropathy with an average duration of symptoms of 4.9 ± 3.5 years 20/52 (38%) had signs suggestive of neuropathy with average Neuropathy Impairment Score being 9.0 ± 10.5. After investigations, 21/52 (40%) individuals had clinical features, neurophysiology, and/or skin biopsies consistent with ATTRv-PN (8 large-fiber/13 small-fiber). Six of the 52 individuals (12%) had neuropathies because of alternative etiologies (e.g., diabetes). Real-world experience from the UK national cohort of p.V142I ATTRv indicates that peripheral neuropathy is of a mild severity and less frequent than previously reported.
- 1 October 2025
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 11 (5) , e200304
Open AccessPeripheral Neuropathy in p.Val142Ile (Val122Ile) Variant Hereditary Transthyretin-Mediated Amyloidosis
P.Val142Ile (p.V142I) is one of the most common pathogenic transthyretin (TTR) variants typically presents as transthyretin amyloid cardiomyopathy (ATTRv-CM), although frequent concurrent peripheral nerve involvement has been reported (94%). We aimed to characterize the polyneuropathy in p.V142I ATTR amyloidosis (ATTRv-PN) from the UK amyloidosis cohort. We performed a retrospective cohort study of all confirmed p.V142I Variant Transthyretin Amyloidosis (ATTRv) individuals in the National Hospital for Neurology and Neurosurgery Inherited Neuropathy Clinic between January 2019 and October 2024. Because presence of ATTRv-PN was required to access disease-modifying therapy for amyloidosis during this time, all individuals with p.V142I ATTRv were evaluated for neuropathy, providing an unselected cohort. We identified 52 individuals with p.V142I ATTRv among whom the clinical presentation was cardiac in 47 (90%) and neuropathic in 5 (10%). Age at diagnosis was 71.3 ± 12.2 years. Twenty of the 52 individuals (38%) had symptoms suggestive of neuropathy with an average duration of symptoms of 4.9 ± 3.5 years 20/52 (38%) had signs suggestive of neuropathy with average Neuropathy Impairment Score being 9.0 ± 10.5. After investigations, 21/52 (40%) individuals had clinical features, neurophysiology, and/or skin biopsies consistent with ATTRv-PN (8 large-fiber/13 small-fiber). Six of the 52 individuals (12%) had neuropathies because of alternative etiologies (e.g., diabetes). Real-world experience from the UK national cohort of p.V142I ATTRv indicates that peripheral neuropathy is of a mild severity and less frequent than previously reported.
- 26 July 2022
- Published by Wolters Kluwer Health in Neurology
- Vol. 99 (4) , E355-E363
Seizure Duration and Spread Dynamics in MRI-Defined Subtypes of Temporal Lobe Epilepsy
Background and Objectives: MR and PET imaging enables subgroups of Temporal Lobe Epilepsy (TLE) to be defined on the basis of structural pathology. Few studies have examined the variation in electroclinical seizure spread patterns based on imaging findings. We performed a retrospective cohort study, to investigate the electroclinical differences between three specific groups of TLE: MRI-negative PET-positive TLE (MRI-neg TLE), temporal lobe lesion TLE (Lesional TLE) and unilateral hippocampal sclerosis TLE (HS-TLE). Methods: Patients with an electroclinical diagnosis of TLE who had video-scalp EEG recordings of seizures, were identified from the retrospective database of the Austin Comprehensive Epilepsy Program between 2005 and 2019. The cohort was further selected into the three defined groups based on imaging findings, using MRI and FDG-PET. Timings of clinical and electrographic seizure progression were measured, considering the onset, ipsilateral lobar spread, contralateral spread and termination. Durations were compared between groups using linear mixed models with inclusion of demographic and clinical covariates. Results: A total of 105 patients (137 seizures) were included, comprising 36 with MRI-neg TLE (54 seizures), 36 with Lesional TLE (18 lateral versus 16 mesial lesions; 44 seizures) and 33 with HS-TLE (39 seizures). Seizure duration was similar between MRI-neg TLE and Lesional TLE (mean 75.9 vs 71.7 seconds, p=0.91). Further dividing Lesional TLE into medial versus lateral temporal revealed no timing difference either. However, the HS-TLE group had longer total seizure duration (114 seconds) compared to both MRI-neg TLE (p<0.001) and Lesional TLE (p<0.001). Progression of electrographic spread also reflected this pattern, with involvement of extra-temporal regions and then the contralateral hemisphere each taking significantly longer in HS-TLE. Discussion: MRI-neg TLE appears electrographically similar to Lesional TLE, whether mesial or lateral, in the duration of seizures and the timing of electrographic spread. Both appear electrographically different from HS-TLE where propagation is slower, suggesting engagement of different epileptogenic networks or seizure suppression mechanisms. Classification of Evidence: This study provides Class II evidence that the electroclinical features of seizures in HS-TLE are different than MRI-neg TLE and lesional TLE.
- 26 July 2022
- Published by Wolters Kluwer Health in Neurology
- Vol. 99 (4) , E355-E363
Seizure Duration and Spread Dynamics in MRI-Defined Subtypes of Temporal Lobe Epilepsy
Background and Objectives: MR and PET imaging enables subgroups of Temporal Lobe Epilepsy (TLE) to be defined on the basis of structural pathology. Few studies have examined the variation in electroclinical seizure spread patterns based on imaging findings. We performed a retrospective cohort study, to investigate the electroclinical differences between three specific groups of TLE: MRI-negative PET-positive TLE (MRI-neg TLE), temporal lobe lesion TLE (Lesional TLE) and unilateral hippocampal sclerosis TLE (HS-TLE). Methods: Patients with an electroclinical diagnosis of TLE who had video-scalp EEG recordings of seizures, were identified from the retrospective database of the Austin Comprehensive Epilepsy Program between 2005 and 2019. The cohort was further selected into the three defined groups based on imaging findings, using MRI and FDG-PET. Timings of clinical and electrographic seizure progression were measured, considering the onset, ipsilateral lobar spread, contralateral spread and termination. Durations were compared between groups using linear mixed models with inclusion of demographic and clinical covariates. Results: A total of 105 patients (137 seizures) were included, comprising 36 with MRI-neg TLE (54 seizures), 36 with Lesional TLE (18 lateral versus 16 mesial lesions; 44 seizures) and 33 with HS-TLE (39 seizures). Seizure duration was similar between MRI-neg TLE and Lesional TLE (mean 75.9 vs 71.7 seconds, p=0.91). Further dividing Lesional TLE into medial versus lateral temporal revealed no timing difference either. However, the HS-TLE group had longer total seizure duration (114 seconds) compared to both MRI-neg TLE (p<0.001) and Lesional TLE (p<0.001). Progression of electrographic spread also reflected this pattern, with involvement of extra-temporal regions and then the contralateral hemisphere each taking significantly longer in HS-TLE. Discussion: MRI-neg TLE appears electrographically similar to Lesional TLE, whether mesial or lateral, in the duration of seizures and the timing of electrographic spread. Both appear electrographically different from HS-TLE where propagation is slower, suggesting engagement of different epileptogenic networks or seizure suppression mechanisms. Classification of Evidence: This study provides Class II evidence that the electroclinical features of seizures in HS-TLE are different than MRI-neg TLE and lesional TLE.